Elite Diagnostic Limited (JMSE:ELITE)

Elite Diagnostic Cash Flow Statement

Financials in millions JMD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	32.02	26.16	13.35	48.66	1.93
Depreciation & Amortization	166.19	132.16	136.5	104.93	100.01
Other Amortization	3.92	3.07	-0.06	2.59	2.05
Other Operating Activities	0.28	3.04	-0.06	-0.01	-
Change in Accounts Receivable	57.09	-25.85	-57.22	-17.5	-0.25
Change in Accounts Payable	3.66	18.17	29.88	9.56	21.95
Change in Other Net Operating Assets	-2.59	8.07	-10.51	-0.32	-0.64
Operating Cash Flow	260.57	164.81	111.88	147.92	125.04
Operating Cash Flow Growth	58.10%	47.31%	-24.36%	18.29%	87.30%
Capital Expenditures	-92.62	-72.53	-137.75	-275.79	-86.24
Other Investing Activities	0.13	0.09	-20.41	0.01	-
Investing Cash Flow	-92.49	-72.44	-158.15	-275.78	-86.24
Short-Term Debt Issued	9.74	14.09	9.14	5.83	-
Long-Term Debt Issued	400	-	365.42	190	-
Total Debt Issued	409.74	14.09	374.56	195.83	-
Short-Term Debt Repaid	-11.57	-10.52	-8.37	-	-
Long-Term Debt Repaid	-377.92	-112.6	-334.86	-24.26	-14.03
Total Debt Repaid	-389.49	-123.12	-343.23	-24.26	-14.03
Net Debt Issued (Repaid)	20.25	-109.04	31.33	171.57	-14.03
Common Dividends Paid	-	-	-7.07	-31.81	-
Financing Cash Flow	20.25	-109.04	24.27	139.76	-14.03
Net Cash Flow	188.33	-16.66	-22.01	11.9	24.78
Free Cash Flow	167.95	92.29	-25.87	-127.87	38.8
Free Cash Flow Growth	81.98%	-	-	-	-
Free Cash Flow Margin	19.67%	11.24%	-3.43%	-20.48%	7.65%
Free Cash Flow Per Share	0.47	0.26	-0.07	-0.36	0.11
Cash Interest Paid	39.14	62.79	46.87	27.33	21.02
Cash Income Tax Paid	0.31	0.07	-	-	-
Levered Free Cash Flow	163.65	93.6	-19.1	-142.07	42.22
Unlevered Free Cash Flow	181.3	124	1.32	-124.99	55.36
Change in Working Capital	58.16	0.39	-37.86	-8.26	21.05

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.